A critical goal for the Phase 3 clinical trial is also to ensure that the pool of the vaccine test subjects reflects the nation’s diversity, including minorities, older Americans and people with preexisting health conditions. It’s all the more important given the disparate impact the pandemic has had on people who are Black or Latino, as well as other racial minorities.
GWU’s covid-19 clinical trial has met one early goal — getting Black and Latino people to join
Latest News
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below: